We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche’s Tecentriq Meets Phase III Goals in Lung Cancer
Roche’s Tecentriq Meets Phase III Goals in Lung Cancer
A Phase III study of Tecentriq immunotherapy met its primary endpoints by showing improvements in overall survival, regardless of PD-L1 status, when compared with docetaxel chemotherapy in locally advanced or metastatic non-small cell lung cancer.